Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC—COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study

BACKGROUND: This was a phase 1, dose-escalation open-label trial to evaluate the safety and immunogenicity of MVC—COV1901, a SARS-CoV-2 S-2P protein vaccine adjuvanted with aluminum hydroxide and CpG 1018. METHODS: Between September 28 and November 13 2020, 77 participants were screened. Of these, 4...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Szu-Min, Liu, Wang-Da, Huang, Yu-Shan, Lin, Yi-Jiun, Hsieh, Erh-Fang, Lian, Wei-Cheng, Chen, Charles, Janssen, Robert, Shih, Shin-Ru, Huang, Chung-Guei, Tai, I-Chen, Chang, Shan-Chwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233066/
https://www.ncbi.nlm.nih.gov/pubmed/34222848
http://dx.doi.org/10.1016/j.eclinm.2021.100989

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233066/
https://www.ncbi.nlm.nih.gov/pubmed/34222848
http://dx.doi.org/10.1016/j.eclinm.2021.100989

Ejemplares similares